We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Merck (MRK - Free Report) closed at $124.40 in the latest trading session, marking a -2.43% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.19%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Heading into today, shares of the pharmaceutical company had gained 11.97% over the past month, outpacing the Medical sector's gain of 6.06% and the S&P 500's gain of 0.55%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on August 4, 2026. The company is predicted to post an EPS of -$0.26, indicating a 112.21% decline compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.33 billion, indicating a 3.32% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.76 per share and a revenue of $66.75 billion, signifying shifts of -69.27% and +2.68%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 46.53% lower. Currently, Merck is carrying a Zacks Rank of #4 (Sell).
Digging into valuation, Merck currently has a Forward P/E ratio of 46.14. This signifies a premium in comparison to the average Forward P/E of 16.49 for its industry.
Investors should also note that MRK has a PEG ratio of 5.04 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. MRK's industry had an average PEG ratio of 2.65 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 231, which puts it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK - Free Report) closed at $124.40 in the latest trading session, marking a -2.43% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.19%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Heading into today, shares of the pharmaceutical company had gained 11.97% over the past month, outpacing the Medical sector's gain of 6.06% and the S&P 500's gain of 0.55%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on August 4, 2026. The company is predicted to post an EPS of -$0.26, indicating a 112.21% decline compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.33 billion, indicating a 3.32% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.76 per share and a revenue of $66.75 billion, signifying shifts of -69.27% and +2.68%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 46.53% lower. Currently, Merck is carrying a Zacks Rank of #4 (Sell).
Digging into valuation, Merck currently has a Forward P/E ratio of 46.14. This signifies a premium in comparison to the average Forward P/E of 16.49 for its industry.
Investors should also note that MRK has a PEG ratio of 5.04 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. MRK's industry had an average PEG ratio of 2.65 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 231, which puts it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.